Remove

PTC/SB/08a (08-03 )
Approved for use through 07/31/2006. CN/S 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE dt o a collection of information unless it contains a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are requ

U.S.PATENTS

Application Number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

/ ppiloation ranibei		107 10020		
Filing Date		2004-08-12		
First Named Inventor	First Named Inventor Melissa Vass et al.			
Art Unit		3737		
Examiner Name	NYA			
Attorney Docket Numb	er	158982/GEM-0163-P		

10710023

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva	,Columns,Lines wher ant Passages or Rele s Appear	
	1									
If you wish to add additional U.S. Patent citation information please click the Add button.								Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines wher ant Passages or Rele s Appear	
	1	20020042570	A1	2002-0	4-11	Schaldach et al.				
If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Kind Code <sup>2</sup> i Code <sup>4</sup>		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T6	
	1									
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								_		
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city, and/or country where published.							T5			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10710923	
Filing Date		2004-08-12	
First Named Inventor	Melissa Vass et al.		
Art Unit		3737	
Examiner Name	NYA		
Attorney Docket Number		158982/GEM-0163-P	

	1						
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner	Signa	ture	Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1 See Kint Code of USPTO Patient Documents at year USPTO,GOV or METP 6010.4. 2 Enter office that issued the document, by the how-before code (NIPO Standard S13.) 2 For Justinese patient Comments, be included on the year of the reign of the Emperor must procedule be sent in number of the patient counter.

4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. 3 Applicant is to place a check mark here if English languages trenslation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10710923
iling Date		2004-08-12
irst Named Inventor	Melis	sa Vass et al.
Art Unit		3737
Examiner Name NYA		
Attorney Docket Number		158982/GEM-0163-P

#### CERTIFICATION STATEMENT

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,55(c) more than three months prior to the filing of the information disclosure statement. Se 37 CFR 1,97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David Arnold/	Date (YYYY-MM-DD)	2006-07-07
Name/Print	David Arnold	Registration Number	48,894

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public within its to five (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Dex 1450, Alexandria, VA 2231-1450. D NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given cortain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be added that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result information of proceedings or abandomment of the application or existation of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, unsurant to 5 U.S.C. 552/a/m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSA as part of that genery's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.